Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer.
Das DK, Osborne JR, Lin HY, Park JY, Ogunwobi OO. Das DK, et al. Among authors: osborne jr. Transl Oncol. 2016 Jun;9(3):236-41. doi: 10.1016/j.tranon.2016.04.005. Epub 2016 May 19. Transl Oncol. 2016. PMID: 27267842 Free PMC article.
PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer?
Ilboudo A, Chouhan J, McNeil BK, Osborne JR, Ogunwobi OO. Ilboudo A, et al. Among authors: osborne jr. Int J Environ Res Public Health. 2015 Dec 22;13(1):ijerph13010012. doi: 10.3390/ijerph13010012. Int J Environ Res Public Health. 2015. PMID: 26703666 Free PMC article.
Racial/Ethnic Disparities in Genomic Sequencing.
Spratt DE, Chan T, Waldron L, Speers C, Feng FY, Ogunwobi OO, Osborne JR. Spratt DE, et al. Among authors: osborne jr. JAMA Oncol. 2016 Aug 1;2(8):1070-4. doi: 10.1001/jamaoncol.2016.1854. JAMA Oncol. 2016. PMID: 27366979 Free PMC article.
Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.
Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, Vargas HA, Schöder H, Humm JL, Fine SW, Lewis JS, Solomon SB, Osborne JR, Veach D, Sawyers CL, Weber WA, Scher HI, Morris MJ, Larson SM. Fox JJ, et al. Among authors: osborne jr. JAMA Oncol. 2018 Feb 1;4(2):217-224. doi: 10.1001/jamaoncol.2017.3588. JAMA Oncol. 2018. PMID: 29121144 Free PMC article. Clinical Trial.
68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional study.
Martinez J, Subramanian K, Margolis D, O'Dwyer E, Osborne J, Jhanwar Y, Nagar H, Williams N, RoyChoudhury A, Madera G, Babich J, Huicochea Castellanos S. Martinez J, et al. Transl Oncol. 2022 Jan;15(1):101242. doi: 10.1016/j.tranon.2021.101242. Epub 2021 Oct 11. Transl Oncol. 2022. PMID: 34649151 Free PMC article.
Prostate-specific membrane antigen-based imaging.
Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Osborne JR, et al. Urol Oncol. 2013 Feb;31(2):144-54. doi: 10.1016/j.urolonc.2012.04.016. Epub 2012 May 31. Urol Oncol. 2013. PMID: 22658884 Free PMC article. Review.
Utility of FDG-PET in clinical neuroendocrine prostate cancer.
Spratt DE, Gavane S, Tarlinton L, Fareedy SB, Doran MG, Zelefsky MJ, Osborne JR. Spratt DE, et al. Among authors: osborne jr. Prostate. 2014 Aug;74(11):1153-9. doi: 10.1002/pros.22831. Epub 2014 Jun 9. Prostate. 2014. PMID: 24913988 Free PMC article.
Disparities in castration-resistant prostate cancer trials.
Spratt DE, Osborne JR. Spratt DE, et al. Among authors: osborne jr. J Clin Oncol. 2015 Apr 1;33(10):1101-3. doi: 10.1200/JCO.2014.58.1751. Epub 2015 Feb 17. J Clin Oncol. 2015. PMID: 25691679 Free PMC article. No abstract available.
214 results